Biobanking tissue of high quality and fidelity is imperative for cancer genomics research. Since it is a challenging process, we sought to develop a protocol that improves the fidelity and quantity of biobanked primary prostate cancer (CaP) tissue.
We conducted a pilot study evaluating pathologic concordance of biobanked tissue and the radical prostatectomy specimen using either standard protocol (SP) vs. next-generation protocol (NGP).
There were no significant differences in clinical and pathologic characteristics (age, BMI, preoperative PSA, prostate weight, race, final prostatectomy Gleason score, or pathologic tumor and nodal stages) between the two protocol arms. Utilization of the NGP compared to the standard protocol resulted in a significantly higher rate of pathologic concordance between the biobanked and RP specimens (61.8% vs. 37.9%, P = 0.0231) as well as a nearly two-fold increase in the amount of biobanked tumor tissue (330 mm3 vs. 174 mm3, P < 0.001). When looking at relevant clinical and pathologic characteristics, NGP was associated with pathologic concordance on both univariate [OR 2.65 (95% CI 1.13-6.21), P = 0.025] and multivariate analysis [OR 3.11 (95% CI 1.09-8.88), P = 0.034].
Our study validates the NGP as a multidisciplinary approach for improving the fidelity and amount of biobanked primary CaP tissue for future studies. Given the challenges to banking tissue from primary CaP as tumors are often difficult to visualize grossly and are frequently multifocal, optimizing the fidelity and volume of biobanked tissue is an important step forward to improve the generalizability of genomic data as we move towards precision medicine.
Urologic oncology. 2022 Apr 27 [Epub ahead of print]
Peter Y Cai, Muhammad Asad, Michael A Augello, Laura Martin, Christopher Louie, Spyridon P Basourakos, Christopher D Gaffney, Jonathan Shoag, Jiangling Jenny Tu, Francesca Khani, Juan Miguel Mosquera, Massimo Loda, Douglas S Scherr, Christopher E Barbieri, Brian D Robinson
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY., Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY., Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY., Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH., Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY., Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY., Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY., Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY. Electronic address: ., Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY. Electronic address: .